ENSC Ensysce Biosciences, Inc. Stock Quote

ENSC [NASD]

Index	-	P/E	1.23	EPS (ttm)	0.45	Insider Own	33.90%	Shs Outstand	6.22M	Perf Week	-13.47%
Market Cap	13.61M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	-	Perf Month	-48.24%
Income	2.90M	PEG	-	EPS next Q	-	Inst Own	14.50%	Short Float	-	Perf Quarter	-60.44%
Sales	-	P/S	-	EPS this Y	978.50%	Inst Trans	-	Short Ratio	0.77	Perf Half Y	-63.45%
Book/sh	0.30	P/B	1.85	EPS next Y	-	ROA	22.50%	Target Price	-	Perf Year	-95.80%
Cash/sh	0.00	P/C	-	EPS next 5Y	-	ROE	107.10%	52W Range	0.57 - 17.12	Perf YTD	-88.22%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-96.77%	Beta	-0.11
Dividend %	-	Quick Ratio	0.70	Sales past 5Y	-	Gross Margin	-	52W Low	-3.32%	ATR	0.10
Employees	-	Current Ratio	0.70	Sales Q/Q	-70.90%	Oper. Margin	-	RSI (14)	27.92	Volatility	10.16% 10.20%
Optionable	No	Debt/Eq	0.26	EPS Q/Q	-197.80%	Profit Margin	-	Rel Volume	0.88	Prev Close	0.60
Shortable	Yes	LT Debt/Eq	0.26	Earnings	-	Payout	0.00%	Avg Volume	940.29K	Price	0.55
Recom	-	SMA20	-39.93%	SMA50	-47.35%	SMA200	-76.07%	Volume	836,654	Change	-7.08%

May-17-22 08:35AM	ENSC: Test Results Encouraging in Opioid Fight Zacks Small Cap Research -7.09%
May-12-22 04:10PM	Ensysce Biosciences Provides Business Update and Reports First Quarter 2022 Financial Results ACCESSWIRE
May-05-22 05:15PM	Ensysce Biosciences Releases 2021 Annual Shareholder Letter ACCESSWIRE -6.52%
09:15AM	Ensysce Biosciences Announces New Clinical Results from Trials PF614-102 and PF614-MPAR-101 ACCESSWIRE
Apr-20-22 04:05PM	Dr. Lynn Kirkpatrick, Invited Speaker at SMi 22nd Annual Pain Therapeutics Conference in London UK ACCESSWIRE
Apr-18-22 04:05PM	Ensysce Biosciences Announces Appointment of Dr. Nily Osman as Chief Medical Officer ACCESSWIRE
Apr-06-22 09:15AM	ENSC: Ensysce Releases Encouraging Financials Zacks Small Cap Research +8.27%
Mar-31-22 04:05PM	Ensysce Biosciences Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results GlobeNewswire +5.56%
Mar-24-22 05:10PM	Ensysce Biosciences Announces Fourth Quarter and Full Year 2021 Earnings Release Date and Timing of Corporate Update Call ACCESSWIRE
Mar-01-22 05:05AM	ENSC: Ensysce Continues to Progress in Fight Against Opioids Zacks Small Cap Research +12.50%
Feb-23-22 08:31AM	Ensysce Biosciences Announces Participation in the 34th Annual Roth Conference GlobeNewswire
Feb-08-22 04:01PM	Ensysce Biosciences Appoints Industry Veteran Lee Rauch to Board of Directors GlobeNewswire
Jan-31-22 04:01PM	Ensysce Biosciences Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communication Program GlobeNewswire
Jan-27-22 08:30AM	Ensysce Biosciences Announces Results of Special Meeting of Stockholders GlobeNewswire -9.34%
Jan-19-22 04:19PM	Ensysce Biosciences Reminds Stockholders to Vote at Upcoming Special Meeting GlobeNewswire -10.40%
Jan-10-22 08:00AM	Ensysce Biosciences Announces First Cohort Dosing in Bioequivalence (BE) Study of Novel TAAP Opioid GlobeNewswire -7.77%
Jan-05-22 04:05PM	Ensysce Biosciences Announces Participation in the H.C. Wainwright BIOCONNECT Conference GlobeNewswire
Jan-04-22 08:00AM	Ensysce Biosciences Achieves Successful Completion of Part A of Multiple-Ascending Dose (MAD)/Bioequivalents (BE) Trial for its Next Generation Opioid, PF614 GlobeNewswire
Jan-03-22 02:44PM	Short Squeeze Stocks: ISIG, AVCT and 5 Others Experts Think Are Ready to Pop InvestorPlace -8.72%
Dec-24-21 06:31AM	Ensysce Biosciences (NASDAQ:ENSC) shareholders are up 57% this past week, but still in the red over the last year Simply Wall St.
Dec-15-21 04:05PM	Ensysce Biosciences Announces First Patients Enrolled in Phase 1 Study of PF614-MPAR, its unique technology platform to provide opioid overdose protection GlobeNewswire +17.43%
Dec-09-21 10:29AM	ENSC Stock Alert: What Investors Are Saying About Ensysce Biosciences as Shares Soar Today InvestorPlace +66.78%
08:34AM	ENSC: Tackling the Opioid Crisis Zacks Small Cap Research
07:33AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday InvestorPlace
Nov-30-21 08:00AM	Ensysce Biosciences Announces Clinical Trial Progress of its New Class of Opioids GlobeNewswire
Nov-15-21 05:32PM	Ensysce Biosciences Reports Third Quarter 2021 Financial Results and Recent Corporate Updates GlobeNewswire
Nov-08-21 08:00AM	Ensysce Biosciences Announces Completion of $15 Million Convertible Note Financing GlobeNewswire
Oct-26-21 08:00AM	Ensysce Biosciences Grows its Management Team with Appointment of Dr. Linda Pestano as Chief Development Officer GlobeNewswire +8.72%
Sep-27-21 08:00AM	Ensysce Biosciences Announces $15 Million Convertible Note Financing GlobeNewswire -11.80%
Sep-08-21 08:00AM	Ensysce Biosciences Announces Treatment of First Cohort for Subjects in Clinical Study of its Next Generation Opioid, PF614 GlobeNewswire
Aug-31-21 08:00AM	Ensysce Biosciences Sets September 2021 Conference Schedule ACCESSWIRE
Aug-19-21 08:00AM	Ensysce Biosciences to Host Satellite Symposium with Dr. Jeffrey Gudin at PAINWeek 2021 on September 9, 2021 GlobeNewswire +22.36%
Aug-16-21 04:45PM	Ensysce Biosciences Reports Second Quarter 2021 Financial Results and Recent Corporate Updates GlobeNewswire -11.59%
Aug-05-21 08:00AM	Ensysce Biosciences Announces Notice of Allowance from the U.S. Patent and Trademark Office for Patent Entitled Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof GlobeNewswire +11.25%
Jul-26-21 08:00AM	Ensysce Biosciences Bolsters Management Team with Appointments of David J. Kovacs as VP Public Policy and David Tanzer as VP Strategic Development GlobeNewswire -10.25%
Jul-21-21 08:00AM	Ensysce Biosciences to Host Virtual Investor Day on July 27, 2021 GlobeNewswire -11.47%
Jul-08-21 08:00AM	Ensysce Biosciences Receives Notice of Award for Year Three of Multi-Year NIDA Grant for the Clinical Development of its Next Generation Opioid Products with Overdose Protection GlobeNewswire

Ensysce Biosciences, Inc., a clinical-stage biotech company, engages in developing various prescription drugs. The company is developing tamper-proof opioids using Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms. Its products treat severe pain and assist in preventing deaths caused by opioid abuse. The company is based in La Jolla, California.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience